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Abstract Increased levels of extracellular superoxide
dismutase (ecSOD) induced by preconditioning or gene
therapy protect the heart from ischemia/reperfusion injury.
To elucidate the mechanism responsible for this action, we
studied the effects of increased superoxide scavenging on
nitric oxide (NO) bioavailability in a cardiac myocyte-
specific ecSOD transgenic (Tg) mouse. Results indicated
that ecSOD overexpression increased cardiac myocyte-
specific ecSOD activity 27.5-fold. Transgenic ecSOD was
localized to the sarcolemma and, notably, the cytoplasm
of cardiac myocytes. Ischemia/reperfusion injury was
attenuated in ecSOD Tg hearts, in which infarct size was
decreased and LV functional recovery was improved.
Using the ROS spin trap, DMPO, electron paramagnetic
resonance (EPR) spectroscopy demonstrated a significant
decrease in ROS in Tg hearts during the first 20 min of
reperfusion. This decrease in ROS was accompanied by an
increase in NO production determined by EPR using the
NO spin trap, Fe-MGD. Attenuated ROS in ecSOD Tg
myocytes was also supported by decreased production of
peroxynitrite (ONOO-). Increased NO bioavailability was
confirmed by attenuated guanylate cyclase-dependent
(p-VASP) signaling. In conclusion, attenuation of ROS
levels by cardiac-specific ecSOD overexpression increases
NO bioavailability in response to ischemia/reperfusion and
protects against reperfusion injury. These findings are the
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first to demonstrate increased NO bioavailability with
attenuation of ROS by direct measurement of these reactive
species (EPR, reactive fluorescent dyes) with cardiac-specific
ecSOD expression. This is also the first indication that the
predominantly extracellular SOD isoform is capable of
cytosolic localization that affects myocardial intracellular
signal transduction and function.
Keywords NO-bioavailability  Extracellular superoxide
dismutase  Cardioprotection  Ischemia/reperfusion injury 
Peroxynitrite
Abbreviations
aMyHC Alpha-myosin heavy chain
DAF-FM 4-Amino-5-methylamino-20,70-
difluorofluorescein (fluorescent NO probe)
DCFDA 5-(and-6)-Carboxy-20,70-
dichlorodihydrofluorescein diacetate
(fluorescent ROS probe)
DMPO 5,5-Dimethyl-1-pyrroline-N-oxide
(ROS spin trap)
ecSOD Extracellular superoxide dismutase
EPR Electron paramagnetic resonance
Fe-MGD N-methyl-D-glucaminedithiocarbamate
(NO spin trap)
GC Guanylate cyclase
VASP Vasodilator-stimulated protein
WGA Wheat germ agglutinin
Introduction
Extracellular superoxide dismutase (ecSOD) has been
found to play an important role in attenuating the effects of
the reactive oxygen species (ROS) such as superoxide anion
(O2
-), after ischemia/reperfusion injury. Increased oxida-
tive stress caused by ischemia/reperfusion, chronic load, or
heart failure leads to myocardial damage and decreased
function [6]. EcSOD, which catalyzes the dismutation of
O2
- to H2O2 and O2, is a key enzyme that maintains rela-
tively low levels of this important oxygen-derived radical.
Of the three SOD isoforms, ecSOD expression levels are
lowest in the heart based on expression levels and relative
SOD activity. However, overexpression of ecSOD or
treatment with SOD mimetics [31, 32, 60] has been shown
to attenuate oxidative stress and to mitigate tissue dys-
function in cardiovascular disease. EcSOD can be upregu-
lated in response to hypoxia and proinflammatory cytokines
such as IFN-c [38]. Angiotensin II induces ecSOD expres-
sion through the p42/44 MAP kinase pathway [14], while
increased NO production by training upregulates ecSOD
through the p38 MAPK pathway [13]. In the vascular
wall, vasoactive factors such as histamine, vasopressin,
oxytocin, endothelin-1, serotonin and heparin markedly
increase enzyme level [57]. Likewise, studies with targeted
deletion of ecSOD support the antioxidant role of this
enzyme, as the absence of this enzyme was found to exac-
erbate myocardial dysfunction after myocardial infarction or
doxorubicin treatment [29, 59].
Initial hypotheses regarding the mechanism of action of
ecSOD focused on attenuation of ROS levels and the
consequential oxidation of DNA, lipids, and proteins.
Many studies have shown that reperfusion of the ischemic
myocardium increases ROS production and that scaveng-
ing ROS effectively reverses myocardial injury in animal
models [26, 54]. Gene therapy with ecSOD has also been
shown to attenuate ischemia/reperfusion injury [31, 32].
While these experimental observations convincingly dem-
onstrate the protective effects of ecSOD, attenuation of
ROS has not been successful in moderating dysfunction
associated with oxidative stress in clinical scenarios [7].
In addition to the direct actions of ecSOD in attenuating
levels of O2
-, indirect effects of attenuated O2
- have been
postulated to lead to an increase in nitric oxide (NO) bio-
availability. O2
- reacts with NO very rapidly, at diffusion-
limited rates [15, 17]. The reaction of superoxide with NO
leads to the formation of peroxynitrite (ONOO-) [30],
which is a reactive oxidizing agent. Importantly, early after
the identification of endothelial derived relaxation factor
(EDRF) as NO, studies in tissues with high ecSOD levels
recognized that it is destabilized by O2
- in vascular bio-
assays [17, 46]. In these studies, SOD rescued the actions
of EDRF/NO generated from endothelial cells, implicating
O2
- in decreased NO bioavailability. In the context of high
oxidative stress, the reaction with superoxide exacerbates
cellular derangements by removing NO, which would play
a beneficial role in several functions in the heart, and by
producing ONOO-. Further, ONOO- can be protonated to
produce O2
- and nitrogen dioxide, both of which are strong
oxidizing species [28, 43]. The action of ecSOD to atten-
uate O2
- limits the transformation of NO to ONOO-
thereby preserving NO bioavailability for signaling.
NO regulates several systems that affect cardiac func-
tion and survival. It is generated by NO synthases or by
non-enzymatic reduction of nitrite (for review see [51]).
NO is known to play an important role in myocardial
protection [24, 50]. NO generated by iNOS and eNOS has
been found to be a key mediator of myocardial precondi-
tioning [5]. Recently, we have demonstrated that NO pro-
tects the myocardium by limiting ROS formation and
thereby preventing mitochondrial permeability transition
[62]. NO has been found to modulate contractile function
through guanylate cyclase (GC) and PKG [3, 39]. It also
exerts direct effects on proteins through the S-nitrosothi-
olation of cysteines [11]. This direct action has been
found to modulate the function of several proteins
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important in myocardial function such as G-protein cou-
pled receptor kinase2 [63], HIF-1a [34], and the ryano-
dine receptor [64].
To examine the relationship between ROS and NO and
to determine whether attenuation of ROS affects NO
bioavailability in the heart, we created a cardiac-specific
ecSOD transgenic mouse. The effects of increased cardiac-
specific ecSOD on ROS and NO were evaluated in vitro
and in vivo in the basal state and with oxidative stress. Our
findings demonstrate that ecSOD-dependent attenuation of
oxidative stress increases NO bioavailability, which
translates into improved functional recovery and decreased
injury in response to myocardial ischemia/reperfusion.
Methods and materials
Materials
Antibodies against phospho-ERK, phospho-AKT, phospho-
p38, phospho-JNK, total-ERK, total-AKT, total-p38, total-
JNK, phospho-VASP, VASP, phospho-GSK, total GSK,
GAPDH, and histone H3 were purchased from Cell Signaling
Technology (Beverly, MA, USA). The b-actin antibody was
purchased from Sigma Aldrich and the cytochrome C anti-
body from Abcam. Diethylenetriaminepentaacetic acid was
purchased from Sigma Aldrich, USA. The oxygen radical
spin trap 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) was
obtained from Dojindo Laboratories, Kumamoto, Japan.
N-Methyl-D-glucaminedithiocarbamate (MGD) was synthe-
sized as described previously [53].
Cardiomyocyte-specific ecSOD transgenic mice
The mouse 5.5 kb aMyHC promoter (kindly provided by
Jeff Robbins) [18] was used to direct cardiomyocyte-spe-
cific expression of the mouse ecSOD transgene. The mouse
ecSOD cDNA was cloned into a SalI–HindIII site of the
aMyHC promoter and the linearized construct injected into
C57Bl/6 pronuclei. Transgenic offspring were identified by
PCR amplification of the transgene. EcSOD Tg mice used
in experiments were produced by crossing with WT
C57BL/6 mice with littermate WT mice used as controls.
Langendorff perfused heart preparation for LV
function, reperfusion injury, spin trapping and ONOO-
measurements
All procedures were conducted under the approval of the
University of Louisville IACUC in accordance with the
NIH Guide for the Care and Use of Laboratory Animals
(DHHS publication No. [NIH] 85-23, rev. 1996) as previ-
ously described [9]. LV function, EPR, and reperfusion
injury were measured in hearts isolated from WT and ec-
SOD Tg mice as previously described [62]. The NO spin
trap, Fe-MGD (0.5 mM) [67], was administered immedi-
ately upon reperfusion (1 ml/min) through a side arm above
the aorta cannula. Perfusate was collected at 20-s intervals
and immediately frozen in liquid nitrogen. EPR spectra
were recorded as described previously [61, 62]. ONOO-
release during reoxygenation was measured as luminol
chemiluminescence in perfusate collected at reperfusion
with infusion of 40 lM luminol (ScienceLab.com, Hous-
ton, TX, USA) prepared in 5 mM Na2CO3, pH 9.2, during
the first 2 min of reperfusion as described [61].
In situ coronary occlusion and infarct size measurement
Hearts were infarcted by coronary artery ligation and rep-
erfused in situ as previously described [9]. Infarct size was
assessed 24 h after coronary reperfusion. The non-ischemic
region was stained with Evan’s blue (1–1.5 ml, 1 %)
injected through the retrobulbar plexus after re-ligation of
the coronary artery. The heart was then arrested by intra-
ventricular injection of 0.1 ml KCl (3 M)–CdCl (0.1 M)
solution, excised, weighed, rinsed in PBS, and then cut into
1-mm cross-sections. Viable myocardium was determined
by TTC staining (1 %, 37 C) for 15 min. Images were
digitally acquired and the infarct size determined as pre-
viously described [20].
Cardiac myocyte isolation for hypoxia/reoxygenation
studies
Adult cardiomyocytes from WT and ecSOD Tg mice were
isolated as previously described [25]. NO bioavailability
after hypoxia/reoxygenation was measured in myocytes
plated on polycarbonate microwell plates (Nunc, Thermo
Fisher) incubated with either the NO sensitive fluores-
cent dye 4-amino-5-methylamino-20,70-difluorofluorescein
(DAF-FM, 10 lM, Molecular Probes) for 1 h. ROS and
ONOO- were measured using the ROS sensitive dye
5-(and-6)-carboxy-20,70-dichlorodihydrofluorescein diacetate
(carboxy-DCFDA, 10 lM, Molecular Probes) and ONOO-
indicators luminol and HKGreen3 [44] (5 lM, a kind gift
from Dr. Dan Yang, University of Hong Kong) for 1 h. The
culture medium was then immediately changed to ischemic
buffer. Myocytes were treated under hypoxic conditions for
30 and 90 min and reoxygenated as previously described
[25]. The microwell plate inserts were placed in normoxic-
modified KH buffer containing 1.26 mM Ca2? and the fluo-
rescent signal measured immediately (DCFDA, 495/529 nm
abs/em; DAF-FM, 495/515 nm abs/em; HKGreen3,
485/540 nm abs/em; BioTec Synergy 2, Winooski, USA).
The signal from each well was subsequently normalized to
protein content determined by Bradford assay.
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Western analysis for cell signal transduction
Hearts from WT and ecSOD Tg mice were isolated, frozen,
pulverized, and homogenized in buffer and homogenates
prepared and processed for PAGE and Western analysis as
described previously [25].
EcSOD activity measurement in whole hearts
Hearts from WT and ecSOD Tg mice were homogenized
and sonicated in ice-cold homogenization buffer containing
(in mM) 20 HEPES, 1 EGTA, 210 mannitol, and 70
sucrose. SOD activity was determined in a 1,500 g super-
natant (Cayman). EcSOD was isolated by concanavalin
A-Sepharose 4B (Sigma Aldrich) chromatography [35].
EcSOD was eluted with 0.5 M a-methyl-D-mannoside and
SOD activity determined.
Detection of intracellular ecSOD distribution
by immunofluorescence microscopy
Extracellular superoxide dismutase localization in myo-
cytes was assessed by immunofluorescent confocal
microscopy (Zeiss LSM 510) in 4 lm paraffin sections
stained with anti-rabbit ecSOD-IgG (1:50) and counter-
stained with FITC-conjugated wheat germ agglutinin
(WGA-FITC, Molecular Probes) to detect plasma mem-
brane, and 40,6-diamidino-2-phenylindole (DAPI) for
nuclear staining.
Statistical analysis
All data are presented as mean ± SEM. Differences
between groups were compared by unpaired Student’s
t test. Comparisons among multiple groups or between two
groups at multiple time-points were performed by either
one-way or two-way ANOVA followed by paired or
unpaired Student’s t test with Bonferroni correction. Mul-
tiple time-point comparisons between ecSOD Tg and WT
mice were performed with two-way repeated-measures
ANOVA (Graphpad 5.03, San Diego, CA, USA). A value
of P \ 0.05 was considered significant.
Results
Extracellular superoxide dismutase gene therapy and
ischemic preconditioning with increased ecSOD have been
shown to protect the myocardium from ischemia/reperfu-
sion injury. To further investigate the mechanisms by
which ecSOD protects the myocardium from ischemia/
reperfusion injury, we generated cardiac-specific ecSOD
Tg mice under the direction of the aMyHC promoter.
EcSOD expression was increased in heart and cardiac
myocytes of ecSOD Tg mice (Fig. 1a; Supplemental
Figure 1A) resulting in a 27.5-fold increase in ecSOD
activity (Fig. 1b), which, however, did not significantly
increase total myocardial SOD activity (Fig. 1c). EcSOD is
typically associated with the extracellular matrix due to the
presence of a carboxyterminal heparin-binding domain
[27, 35]. Low levels of endogenous ecSOD relative to
CuZn- or Mn-SOD have led to the conclusion that this
isoform is predominantly extracellular [36, 37, 47]. Few
studies have demonstrated that ecSOD can also be local-
ized to other subcellular locations [41, 42]. We found that
ecSOD was strongly co-localized to the plasma membrane
(with WGA) in sections from Tg hearts (Fig. 1d). How-
ever, we were surprised to also find ecSOD within the
cytoplasm of myocytes in Tg hearts (Fig. 1d). These results
suggest that, when overexpressed, ecSOD is not exclu-
sively associated with the extracellular membrane in the
heart and may be distributed throughout the cytoplasm.
To determine whether increased myocyte-specific ec-
SOD could attenuate ischemia/reperfusion injury, Lange-
ndorff perfused WT and ecSOD Tg hearts were subject to
30 min global ischemia followed by 45 or 90 min reper-
fusion. LV functional recovery after 30 min of global
ischemia was significantly improved in ecSOD Tg mice
compared to WT (Fig. 2a–c). This improvement in recov-
ery was manifest as increased LV-developed pressure
(Fig. 2a), decreased diastolic pressure (Fig. 2b), and
increased LV dP/dtmax (Fig. 2c). Infarct size, assessed by
TTC staining in WT hearts with 45- and 90-min reperfu-
sion, was similar (Fig. 2d). In ecSOD Tg hearts, infarct size
was significantly decreased in both 45- and 90-min reper-
fusion groups (Fig. 2d). In vivo, coronary artery occlusion
resulted in significantly smaller infarcts in ecSOD Tg mice
in comparison with WT mice (ecSOD Tg, 26 ± 2 % of the
risk region; WT, 45 ± 4 %, P \ 0.05; Table 1; Fig. 3).
Collectively, these data demonstrate that myocyte-specific
ecSOD overexpression confers myocardial protection
against ischemia/reperfusion injury in vitro and in vivo,
resulting in improved functional recovery and decreased
infarct size.
An increase in ecSOD expression would be expected to
diminish ROS levels. To verify this, ROS were measured
by EPR spectroscopy in Langendorff perfused hearts. WT
hearts perfused with the spin trap, DMPO, at the onset of
reperfusion showed a rapid burst of ROS that declined
quickly by 80 s (Fig. 4a). The spike in ROS upon reper-
fusion was significantly attenuated in ecSOD Tg hearts.
ROS levels rapidly returned to a stable value in ecSOD Tg
hearts and in WT hearts; however, in the ecSOD Tg hearts
ROS declined to a lower level than that in WT hearts. To
verify that the effect of ecSOD on ROS was specifically
associated with myocytes, ROS levels were measured in
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isolated myocytes using the fluorescent indicator DCFDA
under ambient O2 levels and after 30 min hypoxia
(1 % O2). Similar to the results obtained through EPR
analysis, ROS levels upon reoxygenation after hypoxia
were markedly attenuated in myocytes from ecSOD Tg
hearts compared with those from WT hearts (Fig. 4c).
Previous work, primarily in vascular biology, has sug-
gested that a decrease in ROS would lead to an increase in
NO bioavailability as a consequence of decreased reaction
between O2
- and NO and decreased formation of ONOO-
[17, 46]. This notion of increased NO bioavailability was
extrapolated from functional endpoints, such as vessel
relaxation. Since ROS levels were attenuated in isolated
hearts (by EPR) and in isolated myocytes (by DCFDA
fluorescence), we directly measured NO in isolated hearts
using the NO spin trap, Fe-MGD, to determine whether the
decrease in ROS would be accompanied by an increase in
NO. Hearts were perfused with Fe-MGD under normoxic
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Fig. 1 Cardiac myocyte-
specific ecSOD overexpression.
Mouse ecSOD was
overexpressed in cardiac
myocytes under the direction of
the mouse aMyHC promoter.
a Western analysis
demonstrates a marked increase
in ecSOD in ecSOD Tg hearts
relative to those of WT
littermates. b EcSOD was
purified from Cu–Zn SOD and
Mn-SOD by concanavalin A
chromatography. EcSOD
activity was significantly
increased in transgenic hearts/
myocytes. c Total SOD activity
was slightly, but not
significantly, increased in
ecSOD Tg hearts. d Confocal
microscopy localizes transgenic
ecSOD to the myocyte cytosolic
space (arrows right
magnification) in addition to the
extracellular space (arrow
middle magnification) defined
by wheat germ agglutinin
(WGA) staining. Values are the
mean ± SEM (n = 3).
**P \ 0.01
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conditions prior to ischemia and at the onset of reperfusion.
Baseline NO levels tended to be higher in ecSOD Tg than
in WT hearts (P = 0.06, Fig. 5a). In ecSOD Tg hearts, NO
levels increased dramatically after reperfusion peaking at
60 s and then returning to a level that was slightly elevated
compared to WT. In WT hearts, NO levels after reperfu-
sion increased slightly but insignificantly over normoxic
baseline levels unlike the peak observed in ecSOD Tg
Fig. 2 EcSOD overexpression
protects the heart from
dysfunction and injury
following ischemia/reperfusion
in vitro. Cardiac function and
infarct size were measured in
isolated WT and ecSOD Tg
hearts perfused using the
Langendorff model. Cardiac
function a LV developed
pressure (LVDP), b LV end
diastolic pressure (LVEDP) and
c LV dP/dtmax was measured in
hearts that had undergone
30 min of global ischemia
followed by 90 min of
reperfusion at 37 C. d EcSOD
overexpression limited infarct
size after 30 min ischemia.
Infarct size, defined by TTC
staining and measured as
percent of risk region, was
significantly decreased in hearts
reperfused for either 45 or
90 min. Values are the
mean ± SEM (n = 6–11).
*P \ 0.05, **P \ 0.01
Table 1 Age, heart sizes, left ventricle size, risk region, infarct area, and temperature and heart rate during ischemia
Phenotype Age
(weeks)
HW/BW Planimetry results Heart rate and temperature during ischemia
LV Risk region Infarct size 15 min 30 min
mg mg % of
LV
mg % of
RR
% of
LV
Temp (C) HR
(bpm)
Temp (C) HR
(bpm)
WT (n = 7) 15 ± 1 4.2 ± 0.1 61 ± 5 28 ± 2 47 ± 5 13 ± 2 45 ± 4 21 ± 3 37.0 ± 0.2 477 ± 15 37.2 ± 0.1 460 ± 31
ecSOD TG
(n = 5)
22 ± 9 4.9 ± 0.6* 76 ± 3 26 ± 1 38 ± 4 7 ± 0* 26 ± 2* 10 ± 2* 36.9 ± 0.3 474 ± 22 37.1 ± 0.0 494 ± 40
Data are means ± SEM
BW body weight, HW heart weight, RR risk region, LV left ventricle, Temp temperature taken within the thoracic cavity during coronary occlusion,
bpm beats/min
* P \ 0.05 versus WT
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hearts. Protein levels of iNOS and eNOS in ecSOD Tg
hearts measured by Western analysis were not different
from WT hearts (Supplemental Data, figure 1B).
To verify that increased NO was myocyte-specific, NO
was measured in myocytes isolated from ecSOD Tg and WT
hearts using the fluorescent NO indicator DAFDA. Myocytes
constitutively express eNOS and nNOS, associated with
caveolae and sarcoplasmic reticulum, respectively, and are
capable of producing NO [3, 8]. Upon reoxygenation, NO
levels in ecSOD Tg myocytes were significantly higher with
reoxygenation than in WT myocytes (Fig. 5b). The marked
difference in response to reoxygenation between WT and
ecSOD Tg myocytes demonstrates that the attenuation of
ROS is associated with increased NO bioavailability and
supports the finding of increased NO bioavailability observed
in Langendorff perfused hearts. Attenuated ROS levels in the
ecSOD Tg heart would lead to decreased levels of ONOO-
and decreased injury with reperfusion [61]. ONOO- levels
were measured by luminol chemiluminescence [61] and
HKGreen3 fluorescence [44] in isolated myocytes from Tg
and WT hearts under basal conditions and with hypoxia
reoxygenation. ONOO- levels in Tg myocytes were signif-
icantly lower than in WT myocytes with luminol and
HKGreen3 detection (Fig. 6a, b). The ONOO- burst
observed in the first 30 min of reoxygenation was attenuated
in myocytes from ecSOD Tg hearts (Fig. 6c, d) with an
unchanged, but significantly lower ONOO- release in myo-
cytes of ecSOD transgenic mice during the remaining 90 min
of reoxygenation (data not shown). The decrease in ONOO-
in myocytes from ecSOD Tg hearts further supports attenu-
ated ROS release with increased ecSOD and provides an
additional mechanism for improved protection from reper-
fusion injury.
To elucidate the mechanisms by which increased NO
and decreased ROS may mediate protection against
ischemia/reperfusion injury, we examined NO signaling
via a GC-dependent pathway by measuring Ser239 phos-
phorylation and activation of the cGMP-dependent protein
kinase (PKG) substrate vasodilator-stimulated protein
(VASP) [55, 56]. VASP levels were similar in hearts from
ecSOD Tg and WT mice (Fig. 7). Phosphorylation of
VASP ser239, which is the preferential PKG site, was
attenuated in ecSOD Tg hearts compared with WT (Fig. 7,
left panels) and this was corroborated in isolated myocytes
(Fig. 7, right panels). This finding supports the increase in
NO bioavailability in ecSOD TG hearts leading to activa-
tion and the subsequent desensitization of GC-dependent
signaling.
To investigate further changes in signaling that may
contribute to the protective effects of decreased oxidative
stress, the status of stress activated and survival signaling
through MAPKs and AKT were examined in ecSOD Tg
and WT hearts. In whole heart homogenates, baseline
levels of total ERK and JNK were unchanged (Fig. 8b, d),
whereas, in comparison with WT hearts, p38 and AKT
levels were significantly decreased in ecSOD Tg (Fig. 8a,
c). Levels of activated phosphorylated p38 and ERK were
higher in ecSOD Tg compared to WT hearts (Fig. 8a, b).
Levels of p-JNK were elevated nearing significance
(p = 0.07) (Fig. 8d). Although p-p38 has increased relative
to total p38, the overall level of p38 has decreased due to
the decrease in total p38 in ecSOD Tg hearts. In response
to ischemic stress, in vitro ischemia/reperfusion injury did
not significantly affect levels of phosphor-ERK or AKT
although total ERK and AKT were slightly increased
(Supplemental figure 3).
Discussion
In this study, we present novel insights into mechanisms
that account for ecSOD-dependent myocardial protection
against ischemia/reperfusion injury helping to close the gap
in understanding the molecular mechanism of ischemia/
reperfusion injury [22, 52]. Using a cardiac-specific ecSOD
Tg mouse, we demonstrate that ecSOD overexpression
leads to both decreased ROS and ONOO- levels and
increased NO bioavailability. This increase in NO aug-
mented signaling through a GC-dependent pathway,
pVASP, demonstrated by its desensitization, while
increasing ERK and decreasing p38 signaling. Our analysis
of the ecSOD Tg mouse also demonstrates that increased
ecSOD expression results in measurable localization of the
protein to intracellular sites. These results constitute the
first report of an assessment of the effects of decreased
ROS levels on NO levels in the heart, measured directly
using spin trapping and a fluorescent indicator. Our data
establish a critical relationship between O2
- scavenging
Fig. 3 In vivo myocardial ischemia/reperfusion injury is attenuated
in the ecSOD Tg mice. In WT and ecSOD Tg mice, a coronary artery
was occluded for 30 min and reperfused for 24 h. Risk and infarct
areas were determined and infarct size expressed as a percent of risk
region. Values are the mean ± SEM (n = 6–7). *P \ 0.05
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and NO in myocardial tissue, and the importance of this
relationship for myocyte signaling and survival after acute
ischemia/reperfusion.
We had previously shown that ecSOD gene therapy in
the rabbit affords protection against ischemia/reperfusion
injury to an extent similar to the late phase of precondi-
tioning [31, 32]. It has also been shown that ecSOD is
upregulated by ischemic preconditioning in the heart [40].
To further determine the capacity of ecSOD to protect the
myocardium from ischemia/reperfusion injury, we created
a cardiac myocyte-specific ecSOD Tg mouse. Our results
demonstrate that myocardial ecSOD overexpression atten-
uates ROS levels in the reperfused heart while affording
protection against tissue injury and dysfunction in the post-
ischemic heart. These results are significant for several
reasons. First, they provide direct evidence that ROS
(measured by the O2
-/OH- spin trap DMPO in whole
hearts and by the fluorescent ROS indicator DCFDA in
isolated myocytes) are decreased by ecSOD. In addition,
they suggest that ecSOD may not only exert its effects via
its archetypal extracellular localization but may also be
present within the cytoplasm exerting influence on O2
-
levels within the myocyte. Myocardial ecSOD expression
accounts for the lowest level of SOD activity of the three
SOD isoforms and is difficult to detect in some cells/tis-
sues. EcSOD gene therapy in rabbits to limit myocardial
injury after infarction showed ecSOD was not expressed in
the heart [31], yet was significantly increased due to that
secreted by the liver to bind myocardial extracellular
matrix [32]. Here total SOD levels were significantly
Fig. 4 Cardiac-specific ecSOD
overexpression attenuates ROS
in the heart. a ROS were
measured by EPR in the
perfusates of Langendorff-
perfused hearts. Hearts were
perfused with the ROS spin trap
DMPO immediately upon
reperfusion and perfusate was
collected for EPR analysis.
b EPR spectra. c The effect of
ecSOD overexpression on ROS
was verified in isolated cardiac
myocytes using the fluorescent
ROS indicator DCFDA. Values
are the mean ± SEM
(n = 5–7). *P \ 0.05
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elevated over basal after release with heparin and prot-
amine (*15 U/mg protein). In humans, preconditioning
increased significantly ecSOD activity in plasma (*25 U/mg
protein) [40]. Unfortunately, myocardial ecSOD could not
be measured in this context. Our study demonstrates that
very small increases in myocardial ecSOD (*4 U/mg
protein) that is distributed through the cytoplasm in addi-
tion to the extracellular matrix is capable of conferring
protection against ischemic injury. In this context, ecSOD
localization at the cell surface due to its carboxyterminal
heparin-binding domain [1] may not be the only indicator
of ecSOD functionality. EcSOD translocation to the
nucleus with oxidative stress [41] and cytoplasmic and
vesicular localization in neurons [42] suggest that intra-
cellular effects may be an important functional domain of
ecSOD-mediated cardioprotection.
While NO-dependent actions have been studied exten-
sively, the preservation or modulation of the NO signal, its
bioavailability, has been relatively less explored due to the
challenge of measuring this labile species. The cardiac-
specific ecSOD Tg mouse offers an opportunity to deter-
mine the effects of modulating O2
- on NO bioavailability.
Direct measurements of NO production by EPR with the
spin trap, Fe-MGD, showed that NO bioavailability was
increased in ecSOD Tg hearts under basal conditions and
NO levels increased dramatically and peaked within 60 s
of reperfusion. The rapid rise of NO in the ecSOD Tg
hearts is likely a consequence of attenuated ROS levels
unmasking NO generation and preservation as a result of
decreased inactivation of NO by O2
- [10]. The increase in
NO immediately after reperfusion would be expected to be
highly beneficial and contribute to myocardial protection
by limiting ROS formation and MPT as we described
previously in the cardiac-specific iNOS Tg mouse [62] and
with eNOS and iNOS gene therapy [33, 58]. In this sce-
nario, ecSOD as well as increased NO could contribute to
attenuating ROS. These findings are notable because levels
of NOS isoforms were unchanged in the ecSOD Tg hearts
(supplement figure, 1 panels b and c), emphasizing the
relationship between ROS and NO. Localization of NOS
isoforms, two of which are sensitive to Ca2?, (eNOS and
nNOS), to myocyte mitochondria has been demonstrated
by different groups [16, 21, 66]. Close proximity of ecSOD
to these mitochondrial NOS isoforms is therefore, likely to
be a key factor in the preservation of NO levels in the
reperfused heart. This view is supported by our findings
that ecSOD is also localized to the cytoplasm as well as
membrane domains, where the greatest levels of ROS
would be expected to be generated during reperfusion. It is
also important to note that increased NO bioavailability
should be cardiac-restricted as increased NOS in blood
cells may exacerbate injury [19].
Increased NO bioavailability and increased ability of
NO to impact its downstream signaling pathway were
verified by examining GC-dependent signal transduction in
hearts from ecSOD Tg mice. The decrease in levels of GC-
dependent VASP phosphorylation demonstrated the func-
tional consequences of increased NO bioavailability. The
decrease in VASP phosphorylation and activation is a
consequence of soluble GC desensitization with increased
NO levels [4, 65]. This observation provides functional
support for the preservation of NO via decreased ROS and
provides a new paradigm in which superoxide levels
regulate not only the extent but also the nature of NO
signaling. In the context of high levels of SOD activity
from both Cu,Zn- and Mn-SOD, this finding may suggest
that ecSOD may have different intracellular targets and
thus exert its effects within different intracellular domains.
S-nitrosocysteine levels in whole hearts and isolated
Fig. 5 NO bioavailability is increased in ecSOD Tg hearts. a NO
levels were measured in ecSOD Tg and WT hearts by EPR
spectroscopy. Isolated hearts were perfused with the NO spin trap,
Fe-MGD, immediately upon reperfusion and the perfusate collected
and analyzed by EPR spectroscopy. b The effect of ecSOD
overexpression on NO bioavailability was verified in isolated
myocytes using the fluorescent NO indicator DAFDA. Values are
the mean ± SEM (n = 6). *P \ 0.05
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myocytes were examined by the biotin switch method,
however, results did not demonstrate an increase in total
levels (data not shown). This does not, however, preclude
increased S-nitrosylation of specific proteins which may
confer cardioprotection through increased NO bioavail-
ability. These observations fit the overall paradigm of
increased NO bioavailability occurring as a result of
increased ecSOD, and suggest that cardioprotection occurs
as a consequence of GC-dependent signal transduction.
Concomitant with NO-dependent signaling, decreased
oxidative stress impacted MAPK and AKT signaling,
which are typically associated with cell stress and survival.
ROS have been shown to activate MAPKs in cardiac
myocytes and fibroblasts and increases in activated p-ERK,
p-AKT [12] and p-p38 [48, 49] are characteristically
known to promote cell survival [2]. In this respect, the
protection from ischemia/reperfusion injury is expected.
However, increased activation of these signaling pathways
would be contrary to expectations if it were based exclu-
sively on ROS levels. Considering studies in ecSOD KO
mice, the decrease in p-p38 in the ecSOD Tg is the only
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Fig. 6 Baseline and hypoxia/
reoxygenation ONOO- levels
are attenuated in myocytes from
ecSOD Tg hearts. ONOO-
levels were measured in
myocytes isolated from WT and
ecSOD hearts detecting luminol
chemiluminescence (a, b) and
HKGreen3 fluorescence (c, d).
Values are the mean ± SEM
(n = 3–4). *P \ 0.05
Fig. 7 Increased NO bioavailability attenuates GC-dependent sig-
naling. Western blots showing the levels of p-VASP and total VASP
in WT and ecSOD hearts. VASP phosphorylation status was used as a
measure of GC-dependent signaling. p-VASP and VASP were
measured in whole heart (left panels) and myocyte (right panels)
homogenates from WT and ecSOD Tg mice by Western analysis.
Values are the mean ± SEM (n = 2–4). *P \ 0.05
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observation congruent with increased activation of p38 in
the KO mice. The complexity of p38 changes in the ecSOD
Tg heart, increased p-p38 in relation to total p38, may
suggest preferential activation of p38b in the context of
increased protection [49]. Increased ERK and JNK acti-
vation are similar to that seen in the ecSOD KO [59]. This
suggests ERK and AKT may be activated by a mechanism
independent of increased ROS, as after ischemia/reperfu-
sion both ERK and AKT phosphorylation were unchanged
(supplement figure 3, panels A–C). NO has been shown to
have a direct effect on PKC increasing its translocation and
activation via tyrosine nitration [16]. This activation results
in complex formation and activation of AKT [66] as well
as ERK and JNK [37]. These studies provide a conceptual
basis for our findings that increased NO bioavailability
with decreased oxidative stress in the ecSOD Tg leads to
activation of these stress-related kinases. P38 has been
shown to be ubiquitinated and degraded by the proteasome
in a c-Jun-dependent manner [45]; however, no direct
evidence exists to support a role for NO or redox balance.
Overall, these changes in ERK, AKT, JNK and p38 would
support a pro-survival environment and would be expected
to contribute to cardioprotection in the ecSOD Tg.
In conclusion, the main novel findings of this study can
be summarized as follows. The cardiac-specific ecSOD
transgenic mouse described in this study provides useful
insights into the relationship between oxidative stress and
NO bioavailability. Using luminol chemiluminescence, the
spin traps, DMPO and Fe-MGD, and the reactive fluores-
cent dyes, DCFDA, DAF and HKGreen3, to directly
measure ROS, NO and ONOO-, we show for the first time
that cardiac myocyte specific ecSOD overexpression
attenuates ROS and ONOO- and that this results in a
concomitant increase in NO. EcSOD, previously consid-
ered to be exclusively extracellular, is capable of localizing
to intracellular domains and although transgenic ecSOD
Fig. 8 MAPK and AKT
signaling in ecSOD Tg hearts.
MAPK and AKT
phosphorylation were measured
in hearts of WT and ecSOD
mice by Western analysis.
Phospho- and total levels of p38
(a), ERK (b), AKT (c), and JNK
(d) were measured in hearts of
WT and ecSOD Tg mice.
Representative Western blots
for summary data; p38 (e), ERK
(f), AKT (g), and JNK (h). Total
kinase levels were normalized
to b-actin and phospho-kinase
levels were normalized to total
kinase. Values are the
mean ± SEM (n = 5–7).
*P \ 0.05
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constitutes a small fraction of total myocardial SOD
activity, it is capable of attenuating overall oxidant stress in
the heart, increasing NO bioavailability resulting in pro-
tection against ischemia/reperfusion injury both in vitro
and in vivo. The augmentation of NO by ecSOD is suffi-
cient to impact NO-dependent GC-signaling pathways.
Finally, the results demonstrate that although ecSOD is
considerably less abundant than other SOD isoforms in the
heart, this enzyme plays a critically important role as an
arbiter of cardiac antioxidant defenses and NO-dependent
actions, and that selective upregulation of ecSOD is
capable of significantly reducing myocardial oxidative
stress and alleviating ischemia/reperfusion injury. The
observation of intracellular localization of ecSOD provides
a potential novel mechanism of action that needs to be
addressed in future studies.
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